The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
XILENTO, TACETAN, TACCASART, XILECAND, DESACAND, CANDESARTAN GPPL, CANDESARTAN BUR, DESARTACAN (Generic Partners Pty Ltd)
Product name
XILENTO, TACETAN, TACCASART, XILECAND, DESACAND, CANDESARTAN GPPL, CANDESARTAN BUR, DESARTACAN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
252 working days (255)
Active ingredients
candesartan cilexetil
Registration type
New generic medicine
Indication
XILENTO, TACETAN, TACCASART, XILECAND, DESACAND, CANDESARTAN GPPL, CANDESARTAN BUR, DESARTACAN (tablets) are indicated for the treatment of hypertension.
XILENTO, TACETAN, TACCASART, XILECAND, DESACAND, CANDESARTAN GPPL, CANDESARTAN BUR, DESARTACAN are indicated for the treatment of patients with heart failure and impaired left ventricular systolic function (left ventricular ejection fraction less than or equal to 40 percent) as add-on therapy to ACE inhibitors or when ACE inhibitors are not tolerated.